Clinical Trial Update: Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Cancer

Drugs mentioned

• FOLFIRINOX
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Nagoya University | Conditions: Borderline Resectable Pancreatic Cancer | Phase 2 | Status: UNKNOWN